SCHEMBL25602302

SCHEMBL25602302

O=[N+]([O-])c1ccc(C2Nc3cc(Cl)cc(Cl)c3C3C=CCC32)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP7 Q93009 2/20 0.57
▸ HPN P05981 2/20 0.54
▸ GAPDH P04406 2/20 0.53
▸ HSPA1A P0DMV8 2/20 0.53
▸ HSPA8 P11142 2/20 0.53
▸ CYBB P04839 1/20 0.53
▸ FPR1 P21462 1/20 0.50
▸ CDK2 P24941 1/20 0.50
▸ NR4A1 P22736 4/20 0.49
▸ AR P10275 3/20 0.47
▸ CD44 P16070 1/20 0.42
▸ MSN P26038 1/20 0.42
▸ PTPN7 P35236 1/20 0.42
▸ EZH2 Q15910 1/20 0.42
▸ POLB P06746 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25602301 0.79 USP7 (0.80) USP7HPNGAPDHHSPA1AHSPA8
SCHEMBL25602307 0.78 USP7 (0.87) USP7HPNGAPDHHSPA1AHSPA8
SCHEMBL25602298 0.75 NR4A1 (0.66) USP7HPNGAPDHHSPA1AHSPA8
SCHEMBL17704810 0.75 USP7 (0.73) USP7HPNGAPDHHSPA1AHSPA8
SCHEMBL25602305 0.75 NR4A1 (0.72) USP7HPNCYBBFPR1CDK2
SCHEMBL25602402 0.74 USP7 (0.58) USP7HPNGAPDHHSPA1AHSPA8
SCHEMBL15726783 0.72 CA12 (0.76) USP7HPNGAPDHHSPA1AHSPA8
SCHEMBL14542508 0.72 NR4A1 (0.80) USP7HPNGAPDHHSPA1AHSPA8
SCHEMBL17464656 0.72 CA12 (0.76) USP7HPNGAPDHHSPA1AHSPA8
SCHEMBL5993987 0.72 USP7 (0.69) USP7HPNGAPDHHSPA1AHSPA8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11672794-B2 Therapeutic targeting of the BAP1 complex in cancer NORTHWESTERN UNIVERSITY (US) 2023-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11672794-B2 Therapeutic targeting of the BAP1 complex in cancer BAP1, MCL1, STUB1 USP7 113/4885HPN 1581/4885GAPDH 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback